Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The array of genome editing strategies based on targeted double-stranded DNA break formation have recently been enriched through the introduction of transcription activator-like type III effector (TALE) nucleases (TALENs). To advance the testing of TALE-based approaches, it will be crucial to deliver these custom-designed proteins not only into transformed cell types but also into more relevant, chromosomally stable, primary cells. Viral vectors are among the most effective gene transfer vehicles. Here, we investigated the capacity of human immunodeficiency virus type 1- and adenovirus-based vectors to package and deliver functional TALEN genes into various human cell types. To this end, we attempted to assemble particles of these two vector classes, each encoding a monomer of a TALEN pair targeted to a bipartite sequence within the AAVS1 'safe harbor' locus. Vector DNA analyses revealed that adenoviral vectors transferred intact TALEN genes, whereas lentiviral vectors failed to do so, as shown by their heterogeneously sized proviruses in target cells. Importantly, adenoviral vector-mediated TALEN gene delivery resulted in site-specific double-stranded DNA break formation at the intended AAVS1 target site at similarly high levels in both transformed and non-transformed cells. In conclusion, we demonstrate that adenoviral, but not lentiviral, vectors constitute a valuable TALEN gene delivery platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the CRISPR system has the potential to be delivered by lentivirus vectors, whereas TALENs do not because of their large size and repeat sequences 23 .”
From Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus (2013) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, although attempts to express TALEN in lentiviral vectors have failed, it has been expressed successfully in adenoviral vectors [82].”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., & Bonas, U. (2009) · Science · doi:10.1126/science.1178811 · Cited by 2,470 · cited 2×
“Crucially, it has been discovered that each individual RVD dictates the binding of the repeat in which it is embedded to a single nucleotide (5,6).”
BackgroundA TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098 · cited 1×
“Hitherto, designer TALEs tested in vitro and in cellula have included those with transcriptional activation or FokI nuclease domains (8,9).”
BackgroundA Simple Cipher Governs DNA Recognition by TAL Effectors
Moscou, M. J., & Bogdanove, A. J. (2009) · Science · doi:10.1126/science.1178817 · Cited by 1,988 · cited 2×
“Crucially, it has been discovered that each individual RVD dictates the binding of the repeat in which it is embedded to a single nucleotide (5,6).”
BackgroundHybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.
Kim, Y. G., Cha, J., & Chandrasegaran, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1156 · Cited by 1,889 · cited 4×
“Hitherto, designer TALEs tested in vitro and in cellula have included those with transcriptional activation or FokI nuclease domains (8,9).”
BackgroundInfluentialGenetic engineering of human pluripotent cells using TALE nucleases
Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S., Gao, Q., Cassady, J. P., Cost, G. J., Zhang, L., Santiago, Y., Miller, J. C., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1927 · Cited by 1,135
Xanthomonas AvrBs3 Family-Type III Effectors: Discovery and Function
Boch, J., & Bonas, U. (2010) · Annual Review of Phytopathology · doi:10.1146/annurev-phyto-080508-081936 · Cited by 978 · cited 1×
“5 repeat units with circa 34 residues each (7).”
BackgroundRepeat instability: mechanisms of dynamic mutations
Pearson, C. E., Edamura, K. N., & Cleary, J. D. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1689 · Cited by 924 · cited 1×
“Indeed, examples of both physiological and functionimpairing processes associated with instability of tandem repeats are copious and cover virtually all biological systems from viruses and prokaryotes to eukaryotes (44-46).”
BackgroundLombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845 · cited 1×
“of transposases, homing endonucleases and zinc finger nucleases (33-36).”
BackgroundA novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity
Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., & Cathomen, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr597 · Cited by 714 · cited 2×
“A TALEN pair (Supplementary Figure S1) targeting intron 1 of the PPP1R12C locus (AAVS1 target site: 50-TCTGTCCCCTCCACCCCAC-spacer-GACAGGAT TGGTGACAGAA-30) were generated by Golden Gate cloning, as previously described (9).”
BackgroundMethodSelf-citationRepeat instability : mechanisms of dynamic mutations
Pearson, C. E. (2005) · Medical Entomology and Zoology · Cited by 711
Research works printed but not linked: 1
- Coffin JM Hughes SH Varmus HE Retroviruses 1997 NY Cold Spring Harbor Laboratory Press, Cold Spring Harbor 21433340
Cited by
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
The CRISPR/Cas9 system for plant genome editing and beyond
Bortesi, L., & Fischer, R. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.12.006 · Cited by 1,187
“However, TALENs are based on highly repetitive sequences which can promote homologous recombination in vivo (Holkers et al., 2013).”
BackgroundA guide to genome engineering with programmable nucleases
Kim, H., & Kim, J.-S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3686 · Cited by 1,163
Optical control of mammalian endogenous transcription and epigenetic states
Konermann, S., Brigham, M. D., Trevino, A. E., Hsu, P. D., Heidenreich, M., Cong, L., Platt, R. J., Scott, D. A., Church, G. M., & Zhang, F. (2013) · Nature · doi:10.1038/nature12466 · Cited by 803
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 719
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9
Gupta, R. M., & Musunuru, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72992 · Cited by 492
Engineering of CRISPR/Cas9‐mediated potyvirus resistance in transgene‐free Arabidopsis plants
Pyott, D. E., Sheehan, E., & Molnar, A. (2016) · Molecular Plant Pathology · doi:10.1111/mpp.12417 · Cited by 413
Genome-Editing Technologies: Principles and Applications
Gaj, T., Sirk, S. J., Shui, S.-L., & Liu, J. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023754 · Cited by 381
“However, TALENs are substantially larger than ZFNs, and have a highly repetitive structure, making their efficient delivery into cells through the use of lentivirus (Holkers et al. 2013) or a single adeno-associated virus (AAV) particle challenging.”
BackgroundSelf-citationOptimization of scarless human stem cell genome editing
Yang, L., Guell, M., Byrne, S., Yang, J. L., De Los Angeles, A., Mali, P., Aach, J., Kim-Kiselak, C., Briggs, A. W., Rios, X., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt555 · Cited by 380
“Although the modular nature of RVDs simplifies TALEN design, their repetitive sequences complicate methods for synthesizing their DNA constructs (7–10) and also impair their use with lentiviral gene delivery vehicles, most likely by causing sequence instabilities (11).”
BackgroundTechnological Developments in lncRNA Biology
Jathar, S., Kumar, V., Srivastava, J., & Tripathi, V. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-5203-3_10 · Cited by 349
Origins of Programmable Nucleases for Genome Engineering
Chandrasegaran, S., & Carroll, D. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.014 · Cited by 325
“Viral-mediated delivery of large highly repetitive genes encoding TALENs into mammalian cells is also problematic [92].”
Vouillot, L., Thélie, A., & Pollet, N. (2015) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.114.015834 · Cited by 308
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 305
Synthetic biology in mammalian cells: next generation research tools and therapeutics
Lienert, F., Lohmueller, J. J., Garg, A., & Silver, P. A. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3738 · Cited by 280
CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems
Jiang, W., & Marraffini, L. A. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104441 · Cited by 208
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 189
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Ortega, D. G., & Deng, W. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 173
“35,36 Last but not least, the newly emerged CRISPR/Cas9 offers precise genetic modi fi cations of T cells while improving their effectiveness against cancer cells.”
BackgroundMethodmegaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering
Boissel, S., Jarjour, J., Astrakhan, A., Adey, A., Gouble, A., Duchateau, P., Shendure, J., Stoddard, B. L., Certo, M. T., Baker, D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1224 · Cited by 173
“5 repeats also facilitates codon divergence of the TAL effector repeats to allow packaging into retroviral vectors, where recombination among TAL effector RVDs during reverse transcription can be problematic (25).”
BackgroundCRISPR/Cas9: A powerful tool for crop genome editing
Song, G., Jia, M., Chen, K., Kong, X., Khattak, B., Xie, C., Li, A., & Mao, L. (2016) · The Crop Journal · doi:10.1016/j.cj.2015.12.002 · Cited by 171
TALE and TALEN genome editing technologies
Becker, S., & Boch, J. (2021) · Gene and Genome Editing · doi:10.1016/j.ggedit.2021.100007 · Cited by 169
How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance
Gholizadeh, P., Köse, Ş., Dao, S., Ganbarov, K., Tanomand, A., Dal, T., Aghazadeh, M., Ghotaslou, R., Ahangarzadeh Rezaee, M., Yousefi, B., et al. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s247271 · Cited by 159
Engineered Viruses as Genome Editing Devices
Chen, X., & Gonçalves, M. A. F. V. (2016) · Molecular Therapy · doi:10.1038/mt.2015.164 · Cited by 151
Self-citationLiu, J., Gaj, T., Patterson, J. T., Sirk, S. J., & Barbas III, C. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085755 · Cited by 149
“[25].”
Self-citationCharacteristics of Genome Editing Mutations in Cereal Crops
Zhu, C., Bortesi, L., Baysal, C., Twyman, R. M., Fischer, R., Capell, T., Schillberg, S., & Christou, P. (2016) · Trends in Plant Science · doi:10.1016/j.tplants.2016.08.009 · Cited by 162
Maggio, I., Holkers, M., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2014) · Scientific Reports · doi:10.1038/srep05105 · Cited by 141
Self-citationAdenoviral vector DNA for accurate genome editing with engineered nucleases
Holkers, M., Maggio, I., Henriques, S. F. D., Janssen, J. M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Nature Methods · doi:10.1038/nmeth.3075 · Cited by 138
Self-citationTALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts
Bernstein, D. L., Le Lay, J. E., Ruano, E. G., & Kaestner, K. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77321 · Cited by 137
“The highly repetitive sequences of the TALE modules have a strong tendency to recombine (13), and we addressed this issue by reengineering the TALE repeat moieties to minimize direct DNA repeats without altering the coding sequence.”
BackgroundDelivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
TALEN-mediated genome editing: prospects and perspectives
Wright, D. A., Li, T., Yang, B., & Spalding, M. H. (2014) · Biochemical Journal · doi:10.1042/bj20140295 · Cited by 158
Genome editing at the crossroads of delivery, specificity, and fidelity
Maggio, I., & Gonçalves, M. A. F. V. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.02.011 · Cited by 132
Self-citationCurrent and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN
Ain, Q. U., Chung, J. Y., & Kim, Y.-H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.036 · Cited by 130
Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells
Liu, J., Gaj, T., Yang, Y., Wang, N., Shui, S., Kim, S., Kanchiswamy, C. N., Kim, J., & Barbas, C. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.117 · Cited by 137
Self-citationMock, U., Machowicz, R., Hauber, I., Horn, S., Abramowski, P., Berdien, B., Hauber, J., & Fehse, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv469 · Cited by 126
“Efficient TALEN delivery, particularly into primary cells, remains a challenge (33,34).”
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri, M., & Mussolino, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137333 · Cited by 145
“In the genome editing field, however, AdV vectors offer the unique opportunity to deliver large transgenes, such as designer nucleases, in a transient manner, thus enabling precise genome editing approaches directly upon in vivo administration [73].”
BackgroundSelf-citationEngineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 118
“Engineering TALEs to target new sites is easier than with ZFPs; however, the large size and highly repetitive tracts of TALE proteins made early cloning strategies technically difficult, particularly in the preparation of viral vectors (24, 25).”
BackgroundMethodPRC2 functions in development and congenital disorders
Deevy, O., & Bracken, A. P. (2019) · Development · doi:10.1242/dev.181354 · Cited by 136
Whole genome characterization of sequence diversity of 15,220 Icelanders
Jónsson, H., Sulem, P., Kehr, B., Kristmundsdottir, S., Zink, F., Hjartarson, E., Hardarson, M. T., Hjorleifsson, K. E., Eggertsson, H. P., Gudjonsson, S. A., et al. (2017) · Scientific Data · doi:10.1038/sdata.2017.115 · Cited by 118
Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing
Waryah, C. B., Moses, C., Arooj, M., & Blancafort, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_2 · Cited by 124
Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases
Cai, Y., Bak, R. O., & Mikkelsen, J. G. (2014) · eLife · doi:10.7554/elife.01911 · Cited by 108
“In addition, lentiviral delivery of TALEN-encoding genes is further complicated by frequent recombination between the highly similar sequence repeats encoding the DNA-binding domain (Holkers et al., 2013), and lentiviral delivery of genes encoding re-coded TALE variants has been reported so far only for transcriptiona…”
BackgroundA quick guide to CRISPR sgRNA design tools
Brazelton, A., Zarecor, S., Wright, D. A., Wang, Y., Liu, J., Chen, K., Yang, B., & Lawrence‐Dill, C. J. (2015) · GM crops & food · doi:10.1080/21645698.2015.1137690 · Cited by 115
“…effects; however, construct design complexity due to specific requirements in base composition coupled with a lack of support for the TALEN lentiviral delivery systems (reviewed in (Gaj et al., 2013; Holkers et al., 2013) have held back broad adoption and use of TALENs (Sander and Joung, 2014).”
BackgroundSelf-citationLyu, C., Shen, J., Wang, R., Gu, H., Zhang, J., Xue, F., Liu, X. F., Liu, W., Fu, R., Zhang, L., et al. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0839-8 · Cited by 114
Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies
Castro, N. G. G., Bjelic, J., Malhotra, G., Huang, C., & Alsaffar, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910355 · Cited by 125
“Lentiviral vectors (LVs) offer increased packaging capacity but are not compatible with non-recoded TALENs due to their instability [112].”
BackgroundTAL effectors: tools for DNA Targeting
Jankele, R., & Svoboda, P. (2014) · Briefings in Functional Genomics · doi:10.1093/bfgp/elu013 · Cited by 104
Enabling functional genomics with genome engineering
Hilton, I. B., & Gersbach, C. A. (2015) · Genome Research · doi:10.1101/gr.190124.115 · Cited by 104
“…the larger size and proclivity for recombination of repetitive sequences in TALE proteins may present difficulties in certain applications, such as viral delivery (Holkers et al. 2013), although this issue has been addressed by optimizing the codon usage of repetitive RVDs (Yang et al. 2013b).”
BackgroundDelivery technologies for T cell gene editing: Applications in cancer immunotherapy
Atsavapranee, E., Billingsley, M. M., & Mitchell, M. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103354 · Cited by 111
Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine
Sioson, V. A., Kim, M., & Joo, J. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00199-4 · Cited by 135
Genome Editing in Human Stem Cells
Byrne, S. M., Mali, P., & Church, G. M. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801185-0.00006-4 · Cited by 95
“However, lentiviral vectors are limited by the size of insert that can practically be packaged into the capsid (roughly 7.5 kb) (Yacoub, Romanowska, Haritonova, & Foerster, 2007) and tend to recombine out repetitive DNA sequences (Holkers et al., 2012; Yang et al., 2013).”
InfluentialCCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape
Hütter, G., Bodor, J., Ledger, S., Boyd, M. P., Millington, M., Tsie, M. S., & Symonds, G. P. (2015) · Viruses · doi:10.3390/v7082816 · Cited by 95
“Unlike ZFNs, TALENs recognize only one nucleotide instead of three [14].”
BackgroundIn Vivo Delivery Systems for Therapeutic Genome Editing
Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., Xu, X., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050626 · Cited by 109
“Compare to lentiviral vectors, AdVs-mediated TALEN genome editing therapy can result in analogously high level site-specific DSBs both in transformed cells and non-transformed cells [61].”
BackgroundSelf-citationEngineering nucleases for gene targeting: safety and regulatory considerations
Pauwels, K., Podevin, N., Breyer, D., Carroll, D., & Herman, P. (2013) · New Biotechnology · doi:10.1016/j.nbt.2013.07.001 · Cited by 115
“vectors [157,158], adeno-associated virus vectors [10,159,160]),”
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 98
Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system
Garcia-Bloj, B., Moses, C., Sgro, A., Plani-Lam, J., Arooj, M., Duffy, C., Thiruvengadam, S., Sorolla, A., Rashwan, R., Mancera, R. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11142 · Cited by 91
“Even though TALEs are highly specific [23, 24] programmable DNA-binding proteins [25–28], the repetitive nature of their DBD has posed some concerns for their stability in vivo when transduced with viral vectors [29, 30].”
BackgroundGenome editing in crop improvement: Present scenario and future prospects
Miglani, G. S. (2017) · Journal of Crop Improvement · doi:10.1080/15427528.2017.1333192 · Cited by 84
“Lentiviral vector-mediated gene delivery of ZFNs (Benabdallah et al. 2013; Coluccio et al. 2013; Genovese et al. 2014; Hoban et al. 2015; Lombardo et al. 2007), TALENs (Ebina et al. 2013; Holkers et al. 2013, 2014), and CRISPR/Cas9 (Kabadi et al. 2014; Malina et al. 2013) has been accomplished.”
BackgroundMethodInfluentialHighly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays
Kurata, M., Wolf, N. K., Lahr, W. S., Weg, M. T., Kluesner, M. G., Lee, S. A., Hui, K., Shiraiwa, M., Webber, B. R., & Moriarity, B. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198714 · Cited by 92
Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
Mohamed, H., Gurrola, T., Berman, R., Collins, M., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816515 · Cited by 81
Imaging Specific Genomic DNA in Living Cells
Chen, B., Guan, J., & Huang, B. (2016) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010830 · Cited by 85
“The highly repetitive nature of TALE-coding sequences creates barriers to their delivery using certain viral vectors, such as lentiviruses (55).”
BackgroundNadakuduti, S. S., Buell, C. R., Voytas, D. F., Starker, C. G., & Douches, D. S. (2018) · Frontiers in Plant Science · doi:10.3389/fpls.2018.01607 · Cited by 80
Newer Gene Editing Technologies toward HIV Gene Therapy
Manjunath, N., Yi, G., Dang, Y., & Shankar, P. (2013) · Viruses · doi:10.3390/v5112748 · Cited by 77
“However, although attempts to express TALEN in lentiviral vectors have failed, it has been expressed successfully in adenoviral vectors [82].”
BackgroundMaggio, I., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2016) · Scientific Reports · doi:10.1038/srep37051 · Cited by 77
Self-citationGene therapy for cystic fibrosis: new tools for precision medicine
Lee, J. A., Cho, A., Huang, E. N., Xu, Y., Quach, H., Hu, J., & Wong, A. P. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03099-4 · Cited by 104
“TALEN has shown less off-target and better binding affinity than ZFN, however, the size for cDNA encoding a TALEN (3 kb) can be an issue for delivery into cells with a limited cargo size [42].”
BackgroundSong, Z., Tao, Y., Liu, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444437 · Cited by 89
Duda, K., Lonowski, L. A., Kofoed-Nielsen, M., Ibarra, A., Delay, C. M., Kang, Q., Yang, Z., Pruett-Miller, S. M., Bennett, E. P., Wandall, H. H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku251 · Cited by 76
Precise genome-editing in human diseases: mechanisms, strategies and applications
Zheng, Y., Li, Y., Zhou, K., Li, T., VanDusen, N. J., & Hua, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01750-2 · Cited by 107
“95 Another commonly agreed limitation with TALE arrays is that TALE binding sites need to be initiated with a thymine base in order to achieve maximal binding.”
BackgroundMaggio, I., Stefanucci, L., Janssen, J. M., Liu, J., Chen, X., Mouly, V., & Gonçalves, M. A. F. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1540 · Cited by 75
“Previous work from our laboratory has shown that AdVs, in particular fiber-modified AdVs, are able to introduce functional TALEN and Cas9 nucleases into hardto-transfect, CAR-negative, target cells, including bona fide muscle progenitor cells and non-muscle cells with myogenic capacity (22,23).”
BackgroundSelf-citationGenome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 77
Schiwon, M., Ehrke‐Schulz, E., Oswald, A., Bergmann, T., Michler, T., Protzer, U., & Ehrhardt, A. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.006 · Cited by 76
HIV Diagnosis and Treatment through Advanced Technologies
Zulfiqar, H. F., Javed, A., Sumbal, S., Afroze, B., Ali, Q., Akbar, K., Nadeem, T., Rana, M. A., Nazar, Z. A., Nasir, I. A., et al. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00032 · Cited by 87
“The ability to identify one nucleotide per domain instead of three helps to increase the specificity of technique (135).”
BackgroundNovel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
Mock, U., Riecken, K., Berdien, B., Qasim, W., Chan, E., Cathomen, T., & Fehse, B. (2014) · Scientific Reports · doi:10.1038/srep06409 · Cited by 69
Self-citationCavazza, A., Molina-Estévez, F. J., Reyes, Á. P., Ronco-Díaz, V., Naseem, A., Malenšek, Š., Pečan, P., Santini, A., Heredia, P., Aguilar-González, A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102457 · Cited by 80
“…of dividing and post-mitotic cells have set the stage for initial studies exploring these AdV systems for the delivery of programmable nucleases such as ZFNs, 54 transcription activator-like effector nucleases (TALENs), 55 CRISPR-Cas9 nucleases 56 and, more recently, prime editors (PEs).”
Self-citationIn vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 66
“One disadvantage for the delivery of paired TALE nucleases is their size and their repetitive sequences, making it challenging to utilize viral systems (Holkers et al., 2013).”
New developments in the use of gene therapy to treat Duchenne muscular dystrophy
Jarmin, S., Kymäläinen, H., Popplewell, L. J., & Dickson, G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.866087 · Cited by 75
“In contrast, TALE sequences packaged into lentiviral vectors were found to undergo extensive rearrangements resulting in no expression of the nuclease in the target cells [168].”
BackgroundLysosomal storage diseases: current therapies and future alternatives
Leal, A. F., Espejo-Mojica, A. J., Sánchez, O. F., Ramírez, C. M., Reyes, L. H., Cruz, J. C., & Alméciga-Díaz, C. J. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01935-6 · Cited by 67
Genome-wide CRISPR-Cas9 screening in mammalian cells
Yu, J., & Yusa, K. (2019) · Methods · doi:10.1016/j.ymeth.2019.04.015 · Cited by 72
Designed nucleases for targeted genome editing
Lee, J., Chung, J., Kim, H. M., Kim, D., & Kim, S. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12465 · Cited by 82
The genome editing revolution: A CRISPR‐Cas TALE off‐target story
Stella, S., & Montoya, G. (2016) · BioEssays · doi:10.1002/bies.201670903 · Cited by 64
Use of gene-editing technology to introduce targeted modifications in pigs
Ryu, J., Prather, R. S., & Lee, K. (2018) · Journal of Animal Science and Biotechnology · doi:10.1186/s40104-017-0228-7 · Cited by 64
“Both ZFN and TALEN require assembling an array to make each set, which is complex and time-consuming [73, 74].”
Qiao, M., Li, R., Zhao, X., Yan, J., & Sun, Q. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.014 · Cited by 65
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62
“However, TALENs are difficult to clone and deliver with lentivirus because the transcription activator-like effector (TALE) repeats have a propensity to recombine (55).”
BackgroundTakeuchi, R., Choi, M. Y., & Stoddard, B. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321030111 · Cited by 72
“In contrast, TALENs and CRISPRs can be more easily reprogrammed to a wider range of DNA sequences (11), but their lengthy reading frames may complicate packaging and delivery in certain contexts and applications (12).”
BackgroundImproved Cell-Penetrating Zinc-Finger Nuclease Proteins for Precision Genome Engineering
Liu, J., Gaj, T., Wallen, M. C., & Barbas, C. F. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.6 · Cited by 61
Self-citationCurrent progress of genome editing in livestock
Lee, K., Uh, K., & Farrell, K. (2020) · Theriogenology · doi:10.1016/j.theriogenology.2020.01.036 · Cited by 68
“Unlike ZFN or TALEN assemble, which requires a series of ligation reactions to form an array [35, 36], CRISPR/Cas9 system can be assembled by inserting a 20 bp target DNA sequence into a targeting vector [8].”
BackgroundHigh‐throughput screens in mammalian cells using the CRISPR‐Cas9 system
Peng, J., Zhou, Y., Zhu, S., & Wei, W. (2015) · FEBS Journal · doi:10.1111/febs.13251 · Cited by 73
CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities
Roy, B., Zhao, J. C., Yang, C., Luo, W., Xiong, T., Li, Y., Fang, X., Gao, G., Singh, C. O., Madsen, L., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00240 · Cited by 67
Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer
Sarvari, P., Sarvari, P., Ramírez‐Díaz, I., Mahjoubi, F., & Rubio, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179521 · Cited by 74
Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression
Seem, K., Kaur, S., Kumar, S., & Mohapatra, T. (2024) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2024.2320659 · Cited by 69
“However, the tandem repeats of the tAle make it susceptible to recombination-related rearrangement (Holkers et al. 2013), while the size of the repeats creates difficulty in its delivery into the targeted cells using a viral (e.g. lentivirus) vector (Holkers et al. 2013).”
BackgroundSaydaminova, K., Ye, X., Wang, H., Richter, M., Ho, M., Chen, H., Xu, N., Kim, J., Papapetrou, E. P., Holmes, M. C., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.57 · Cited by 61
Abbasi, A., & Alexandrov, L. B. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103200 · Cited by 63
From dead leaf, to new life: TAL effectors as tools for synthetic biology
de Lange, O., Binder, A., & Lahaye, T. (2014) · The Plant Journal · doi:10.1111/tpj.12431 · Cited by 61
de Lange, O., Wolf, C., Dietze, J., Elsäesser, J., Morbitzer, R., & Lahaye, T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku329 · Cited by 63
“sequence identity between repeats, useful for some cloning strategies, and possibly alleviating the previously reported problem of recombinatorial repeat loss (32).”
BackgroundGenetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53
“…delivery methods to deliver cDNA/gene editing systems to the lung 69 , robust systems to express ZFNs, TALENs and Cas9 with virus vectors 70;71 , or directly as proteins (or ribonucleoprotein complexes) with modified lentivirus vectors 72;73 offers many opportunities to address these…”
TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus
Shi, B., Li, J., Shi, X., Jia, W., Wen, Y., Hu, X., Zhuang, F., Xi, J., & Zhang, L. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001190 · Cited by 53
Robust identification of mosaic variants in congenital heart disease
Manheimer, K. B., Richter, F., Edelmann, L. J., D’Souza, S. L., Shi, L., Shen, Y., Homsy, J. G., Boskovski, M. T., Tai, A. C., Gorham, J., et al. (2018) · Human Genetics · doi:10.1007/s00439-018-1871-6 · Cited by 52
Systems Metabolic Engineering of Escherichia coli
Choi, K. R., Shin, J. H., Cho, J. S., Yang, D., & Lee, S. Y. (2016) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0010-2015 · Cited by 52
Targeted Genome Editing in Human Cells Using CRISPR/Cas Nucleases and Truncated Guide RNAs
Fu, Y., Reyon, D., & Joung, J. K. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801185-0.00002-7 · Cited by 63
Engineering altered protein–DNA recognition specificity
Bogdanove, A. J., Bohm, A., Miller, J. C., Morgan, R., & Stoddard, B. L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky289 · Cited by 59
“Incorporating variation in repeat backbone sequences could also guard against recombination of TAL effector constructs, which can be problematic in the context of viral systems for delivery (190).”
BackgroundNew and TALENted Genome Engineering Toolbox
Campbell, J. M., Hartjes, K. A., Nelson, T. J., Xu, X., & Ekker, S. C. (2013) · Circulation Research · doi:10.1161/circresaha.113.301765 · Cited by 53
Metadata
- Authors
- Holkers, M., Maggio, I., Liu, J., Janssen, J. M., Miselli, F., Mussolino, C., Recchia, A., Cathomen, T., & Gonçalves, M. A. F. V.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Corresponding author
- Gonçalves, Manuel A. F. V.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-26
- Volume
- 41
- Issue
- 5
- Pages
- e63-e63
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC3597656
- OpenAlex
- W2090787765
- Cited by
- 312
- References
- 62
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 9 · 2022: 10 · 2021: 17 · 2020: 17 · 2019: 16 · 2018: 23 · 2017: 33 · 2016: 42 · 2015: 47 · 2014: 44 · 2013: 21
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- European Commission (222878)
- Universiteit Leiden
- Prinses Beatrix Spierfonds (W.OR11–18)
- Leids Universitair Medisch Centrum
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- TALE nucleases, adenoviral vector, lentiviral vectors, HIV-1-based vectors, AAVS1 safe harbor, genome editing, DNA double-strand breaks, primary human cells
- MeSH terms
- Adenoviridae, Bacterial Proteins, Chromosomes, Human, Deoxyribonucleases, Genetic Vectors, HeLa Cells, Humans, Transduction, Genetic, HIV-1, DNA Breaks, Double-Stranded, Genetic Loci, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.